Biography
Judie Berlier is a Staff Scientist at Thermo Fisher Scientific Inc., USA. Since joining Molecular Probes and continuing through acquisitions and mergers to become a Member of Thermo Fisher Scientific, one constant has been finding and using the technology needed to make novel and useful detection tools for cell biology.
Abstract
Researchers want labeled antibodies that work in their specific applications. Traditional labeling methods include amine-reactive chemistry, thiol-reactive chemistry; periodate oxidation and carbodiimide reactions. Antibodies labeled with these approaches give stable conjugates but can also disrupt antigen binding and are difficult to characterize. In the worst of cases, antibody specificity is lost upon conjugation. A modular copper-less click method for antibody labeling has been shown to be both reproducible and robust and is currently the best option for antibodies where standard chemistries have failed. Antibodies from different sub-classes and species have performed remarkably well in a variety of applications when using this gentle approach. Additionally, this approach allows for the labeling of any existing antibody to be carried out in the presence of BSA, a common stabilizing protein included in the formulation buffer of many commercially available primary antibodies. The method developed uses UDP-GalNAz and the permissive enzyme beta-galactosyltransferase (GalT (Y289L) to produce a site-selective azide label on the N-linked glycans of the heavy chain Fc region far from the antigen binding domain. The azide tagged antibodies are reacted without metal catalysts with any dibenzocyclooctyne (DIBO)-functionalized probe of choice. These biologically unique moieties are inert and stable until the eightmember strained ring reacts with the azide modified antibody forming a stable triazole linkage. This site-specific universal labeling of IgG’s without genetic engineering can be applied to essentially any existing antibody and is currently the preferred method for reproducibly making well-defined antibody conjugates.
Biography
Ruud Van Deursen has completed his PhD from University of Berne. After Postdoctoral studies at Ecole Polytechnique Federale de Lausanne in Switzerland on highthroughput screening, he has joined the Baker Laboratory at the University of Washington in Seattle to work on de novo design of nucelophilic catalysts and expression of disulfide-rich proteins. He has published 16 publications as an author and co-author in the fields of CADD and biocatalysis
Abstract
VX and analogous organophosphorous (OP) compounds display their toxicity by rapidly inhibiting acetylcholinesterases (AChE) in the central nervous system. Upon binding of the OP compound to the catalytic serine, AChE and similar naturally occurring enzymes are frequently reported to undergo ‘aging’. In this process the enzymatic activity is inhibited by irreversible binding of OP compounds to the histidine in the catalytic site. The membrane protein phospholipase A2 (Group VIII) is an exception and is widely resistant against aging, allowing the use of oximes as strong nucleophile in a competitive substitution reaction to restore the catalytic activity. Rosetta has been previously used to create new enzymes based on phosphotriesterases (PTE) obtained from soil bacteria. Further optimization of the catalytic efficiency is however needed. The well conserved α, β-hydrolase-type fold of the phospholipase A2 (group VIII) has been chosen as starting point of this alternate de novo design approach for the reason of the slow aging rates. Key part of this 60 residue minimal core is a flat beta sheet that is composed of 3 parallel strands with a length of 5 residues each. This sheet is surrounded by at least three alpha helices. The small size of this design asks for the introduction of disulfide bonds for stabilization. Herein we present our experimental setup to secrete these de novo designed disulfide-rich proteins using fusion constructs with different leader sequences of the Sec-, SRP- and TAT-secretion pathways.